DOB Logo
Metagenomics Data Analysis Services

Clinical & Human Microbiome Analysis

Bridge the gap between microbiome data and clinical breakthroughs with holistic, patient centric analytical frameworks. Dawn of Bioinformatics Ltd. offers specialized clinical and human microbiome analysis services to translate microbial profiles into actionable biomedical insights. Whether investigating gut skin brain axes, respiratory microbiomes, or tumor associated microbiota, our DawniLab experts apply robust epidemiological models and multi omics integration to link microbial signatures with disease phenotypes, treatment outcomes, and host metadata, accelerating biomarker discovery and personalized therapy development with clinical grade reproducibility.

Request a Quote Explore Features
Clinical & Human Microbiome Analysis

Overview

Dawn of Bioinformatics Ltd. delivers specialized clinical and human microbiome analysis services that convert complex sequencing data into clinically actionable knowledge. We integrate rich patient metadata with species level taxonomic profiles and advanced epidemiological models to reveal microbial signatures associated with disease, treatment response, and long term health outcomes. From gut brain axis studies to oncology microbiomes, our DawniLab team applies rigorous batch effect correction, multivariate association testing, and machine learning to identify robust biomarker panels and support personalized medicine initiatives with the strictest data privacy standards, including HIPAA compliant environments.

Key Features

✓ Metadata integration and multivariate association testing (MaAsLin2, PERMANOVA, random forest).
✓ Enterotyping, dysbiosis indexing, and species level co abundance network reconstruction.
✓ Longitudinal and paired sample designs with rigorous batch effect correction.
✓ Identification of microbial disease markers and therapeutic response predictors.

Demo & Results

In a 200 subject IBD cohort, our analysis identified a panel of 15 microbial species that predicted biologic therapy response with 89% accuracy. Subsequent in vitro validation confirmed Faecalibacterium prausnitzii abundance as a key determinant of mucosal healing, now used to stratify patients before treatment.

Frequently Asked Questions

More Metagenomics